Evergreening, patent challenges, and effective market life in pharmaceuticals
-
Court Denies Generic Drug Manufacturer’s Motion to Dismiss Hatch-Waxman Patent Infringement Action on Jurisdiction Grounds
Pharma Live, , Intellectual Property Rights, 0
the United States District Court for the Southern District of Indiana joined the District of Delaware and Eastern District...
-
Frequently Asked Questions on USPTO
Pharma Live, , Intellectual Property Rights, 0
What XML resources are available at the USPTO to process bulk data? Bulk data uses different versions of XML...
-
Frequently Asked Questions on Patents and Exclusivity
Pharma Live, , Intellectual Property Rights, 0
What is the difference between patents and exclusivity? Patents and exclusivity work in a similar fashion but are distinctly...
-
Amarantus Bioscience Receives Notice Of Allowance For U.S. Patent Application Covering Proprietary Compositions Of Matter And Methods Of Use for manufacture -Courtesy (Biospace)
Pharma Live, , Intellectual Property Rights, 0
SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on...
-
Patent Safe Harbor Applies To Supplemental New Drug Applications
Pharma Live, , Intellectual Property Rights, 0
POSTED BY JACOB D. MOORE AND COURTENAY C. BRINCKERHOFF ON 21 MAY 2015POSTED IN FEDERAL CIRCUIT DECISIONS;INFRINGEMENTOn May 13, 2015, the Federal Circuit confirmed...
-
Channel strategy and orphan drugs – Courtesy (PMLiVe)
Pharma Live, , Intellectual Property Rights, 0
Channel strategy and orphan drugsA channel strategy is a plan for guiding decisions about a product’s distribution channel, ie...
-
The Remicade Biosimilar Patent Dispute
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 10 MARCH 2015POSTED IN BIOSIMILARSWhile Sandoz has grabbed the biosimilar headlines for being the first company to have a...
-
Prepare for the Japanese Patent Opposition System Coming Soon – Courtesy (Global IP Matters)
Pharma Live, , Intellectual Property Rights, 0
The Japanese Patent Act was revised on May 14, 2014 to provide for post-grant oppositions within one year of the rule...
![](https://ml7mn4k5dnn0.i.optimole.com/w:289/h:289/q:eco/f:best/https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)